Hear 50+ Presentations from Top Pharma
As in the past, speaker participation by industry is once again very strong, with presentations from AbbVie, Amgen, AstraZeneca, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Merck, Novartis, and Pfizer, and more. Preview the presentations below:
Emerging Technologies for Gene Therapy R&D
Ivan R. Correia, PhD, Senior Research Fellow & Head, Global Protein Sciences, AbbVie, Inc.
MHC Class I and MHC Class II Immunopeptidomics in Drug Discovery
Domenick Kennedy, PhD, Senior Scientist, Drug Discovery Science and Technology, Discovery Platform Technologies, Chemical Biology and Emerging Therapeutics, AbbVie, Inc.
CAR T Cell Therapy from A-Z
Tara Arvedson, PhD, Executive Director, Oncology Research, Amgen, Inc.
A Bispecific Antibody Agonist of the IL-2ßγ Receptor Promotes in vivo Expansion of CD8+ and NK Cells
Katherine Harris, PhD, Vice President, Discovery, Amgen
Application of Predictive Technologies to Assess Risk of Critical Quality Attributes to Justify Safe Specifications for Patients
Marisa Joubert, PhD, Scientific Director and Group Leader, Amgen
Antibody Discovery Solutions to Complex Membrane Protein Multi-Spanner Targets
Agnieszka Kielczewska, PhD, Principal Scientist, Cell Sciences, Amgen, Canada
Monitoring the Purity and Stability of Multi-Specific Antibodies in vitro and in vivo with CE and CE-MS Intact Mass Analysis
Morgan Stickney, PhD, Scientist, Amgen, Inc.
Antigen Improves Binding of IgGs to Fc Gamma Receptors in SPR Analysis
Wei Wang, PhD, Senior Scientist, Therapeutic Discovery, Amgen
Applications of Cryo-EM in Antibody Characterization
Xinchao Yu, PhD, Principal Scientist, Structural Biology, Amgen, Inc.
High-Throughput Host Cell Protein Profiling via LC-MS/MS in Biopharmaceutical Process Development
Jiao Ma, PhD, Senior Scientist, BioPharmaceuticals R&D Analytical Sciences, AstraZeneca
The Renaissance of Antibody-Drug Conjugates – Progress, Challenges and the Future
Puja Sapra, PhD, Senior Vice President, Biologics Engineering & Oncology Targeted Delivery, AstraZeneca Pharmaceuticals, Inc.
Emerging Methods for the Characterization and Quantitation of High Molecular Weight Species and Particles in AAV Products
George Bou-Assaf, PhD, Scientist, Analytical Development – Product & Technology Development, Biogen
Challenges in Fill-Finish Process for Gene Therapy Drug Product
Kruti Soni, PhD, Scientist, Technical Development, Biogen
Boehringer Ingelheim Pharmaceuticals, Inc.
Optimization of a Transient Antibody Expression Platform Towards High Titer and Efficiency
Elizabeth A. Greene, Scientist IV, Biotherapeutics Molecule Discovery, Boehringer Ingelheim Pharmaceuticals, Inc.
An Introduction to Biopharmaceutical Informatics
Sandeep Kumar, PhD, Senior Research Fellow, Computational Biochemistry and Bioinformatics, Boehringer Ingelheim Pharmaceuticals
Bristol Myers Squibb Co.
Opalescence Measurements: Improvements in Fundamental Knowledge, Identifying Sources of Analytical Biases, and Advanced Applications for the Development of Therapeutic Proteins
Marilia Barros, PhD, Research Investigator, Drug Product Science & Technology, Bristol Myers Squibb Co.
Focused Library Approach to Generate Environment-Responsive Antibodies
Shun Shimizu, PhD, Researcher, Discovery Research, Chugai Pharmaceutical Co. Ltd.
Preclinical Immunogenicity Risk Assessment of Biologics Using CD4 T Cell Proliferation Assays
Robin E. Walsh, MS, Consultant Toxicologist, ImmunoToxicology, Eli Lilly & Co.
Deorphanizing Tough Membrane Targets Using Recombinant Extracellular Vesicles
Shengya Cao, PhD, Senior Scientist, Genentech
In silico and in vitro T Cell Assay to Predict Immunogenicity of Biotherapeutic Products
Sivan Cohen, PhD, Scientist, Genentech
Antibody-Mediated Delivery of Chimeric Protein Degraders
Peter S. Dragovich, PhD, Senior Fellow, Discovery Chemistry, Genentech, Inc.
Delivery of IL-15 to PD1+ Lymphocytes for Cancer Immunotherapy
Patrick Holder, PhD, Scientist, Protein Chemistry, Genentech, Inc.
Development of Neutralizing Antibody Assays: Technical Considerations and Case Studies
Lynn Kamen, PhD, Senior Scientist, BioAnalytical Sciences, Genentech, Inc.
Challenges in Developing PBD-Based ADCs: Early Development Results of a HER2 ADC Containing a Reduced Potency PBD Dimer Conjugated to a Novel HER2 Antibody
Gail D. Lewis Phillips, PhD, Principal Scientist, Discovery Oncology, Genentech, Inc.
Case Study: Activation of an Antibody by a Single Amino Acid Change in the Framework
Wei-Ching Liang, Senior Principal Scientific Researcher, Antibody Engineering, Genentech, Inc.
Investigating the Clinical Impact of the Immunogenicity for a Bispecific Antibody
Wenyu Liu, PhD, Scientist, Bioanalysis, Genentech, Inc.
Sacituzumab Govitecan, a Novel ADC for Solid Tumors
See Phan, MD, PhD. Vice President, Clinical Research Oncology, Gilead Sciences
Improving Antibody Production in Stably Transfected CHO Cells by CRISPR-Cas9-Mediated Inactivation of Genes Identified in a Large-Scale Screen with Chinese Hamster-Specific siRNAs
Ren Liu, PhD, Principal Scientist, Merck & Co., Inc.
Deep Dive into Machine Learning Models for Protein Engineering
Deeptak Verma, PhD, Senior Scientist, Merck & Co.
Characterization of Heterogeneous PEGylated Proteins and Polymer Excipients in the Formulation
Ross Yang, Scientist, Merck Research Labs
Thoughts on De-Risking Approaches for Immunogenicity during Biotherapeutic Candidate Selection
Kyra Cowan, PhD, Senior Director, Global Head of New Biological Entities, Drug Metabolism and Pharmacokinetics, Merck
From Critical Reagent Characterization to Immunogenicity Assay Development
Krisna C. Duong-Ly, PhD, Assoc Principal Scientist, Regulated Bioanalytic, Merck Research Labs
Predicting Antibody Developability Profiles through Experimental and in silico Approaches
Laurence Fayadat-Dilman, PhD, Senior Director, Protein Sciences, Merck Research Laboratories
Stromal Biology: From Basic Science to the Clinic
Viviana Cremasco, PhD, Senior Principal Scientist, Exploratory Immuno-Oncology, Novartis Institutes for BioMedical Research, Inc.
Jonathan E Chang, Principal Scientist, Exploratory Immuno-Oncology, Novartis Institutes for Biomedical Research (NIBR)
All We Need Is Screen: Rethinking the Standard Anti-Drug Antibody Tiered Testing Strategy
Daniel J. Baltrukonis, MA, MBA, Senior Director, Biologics Team Lead, Clinical Assay Group, Clinical Pharmacology, Global Product Development, Pfizer Inc.
Production of Human MOZ Acetyl Transferase Quaternary Complex in Insect Cells
Oleg Brodsky, Senior Principal Scientist, Structural Biology & Protein Sciences, Pfizer Inc.
Protein Production QC – A Protein Chemist’s Toolbox
Oleg Brodsky, Senior Principal Scientist, Structural Biology & Protein Sciences, Pfizer Inc.
Analytical Characterization of DNA and RNA Oligonucleotides by Hydrophilic Interaction Liquid Chromatography-Tandem Mass Spectrometry (HILIC)
Ming Huang, PhD, Scientist, Regeneron Pharmaceuticals, Inc.
Interference in a NAb Assay for a Bispecific mAb from a Prior Therapy and Possible Mitigation Strategy
Susan Irvin, PhD, Staff Scientist, Bioanalytical Strategy, Regeneron
Combinatorial Approaches to Enhance Bispecific Anti-Tumor Efficacy
Eric Smith, PhD, Senior Director, Bispecifics, Regeneron Pharmaceuticals, Inc.
LC-MS-Based Characterization of AAV Capsid Under Denaturing and Native Conditions
Shunhai Wang, PhD, Senior Staff Scientist, Analytical Chemistry, Regeneron Pharmaceuticals, Inc.
Targeting Intracellular WT1 in AML with a Novel RMF-Peptide-MHC Specific T Cell Bispecific Antibody
Alejandro Carpy, PhD, Principal Scientist, Biologics Core Technologies, Roche Innovation Center Munich, Roche Pharma Research & Early Development, pRED
Developing Combination Therapies Based on Bispecific Antibodies and Fusion Proteins
Christian Klein, PhD, Cancer Immunotherapy Discovery, Roche Innovation Center Zurich, Roche Pharma Research & Early Development, pRED
Brain Uptake of Brain Shuttle Gantenerumab (RG6102)
Jens Niewoehner, PhD, Matrix Lead, Roche Pharmaceuticals, Germany
Fully Automating MS Analytics of Next-Generation Protein Therapeutics: From Sample to Report
Miroslav Nikolov, PhD, Senior Scientist & Laboratory Head, Roche, Germany
ADA Characterization for Biotherapeutics: New Methods for the Analysis of the ADA Specificity
Kay-Gunnar Stubenrauch, PhD, Head, Large Molecule Bioanalytical Sciences 1, Roche Diagnostics
Monitoring Adeno-associated Virus (AAV) Capsid Purity, Ratio, and Identity In-process with a High Throughput CE-SDS Platform
Wei-Chiang Chen, PhD, Associate Director, BioProcess Analytics, Genomic Medicine Unit, Sanofi
Introduction to Gene Therapy Product Manufacturing and Analytics
Claire Davies, PhD, Associate Vice President, Bioanalytics, Sanofi
Scott Dooley, Scientist, Analytical Development, Sanofi
Integrated Developability Strategy to Safeguard the Discovery and Optimization of Multi-Specific Biotherapeutics at Sanofi
Melanie Fischer, PhD, Head of Assays and Analytics, Biologics Research, Sanofi
When to Extend Monitoring of Anti-Drug Antibodies for High-Risk Biotherapeutics in Clinical Trials: An Opinion from the European Immunogenicity Platform
Daniel Kramer, PhD, Global Scientific Advisor, Clinical Immunogenicity, Sanofi Aventis Deutschland GmbH
Learning a Language Spoken by Nature: Protein Language Model, a Useful Tool for Protein Engineering
Yu Qiu, PhD, Senior Principal Scientist, Sanofi Genzyme R&D Center
Ultra-Dilute Solution Measurements of Antibody Self-Association
Charles G. Starr, PhD, Scientist, Developability & Preformulation Sciences, Sanofi Group
Tags and Buffers for SPR: Perfecting Proteins to Probe Biophysical Behavior
Maya Rao, PhD, Senior Scientist, UCB, Inc.